Ascletis Pharma Inc. Overview

Ascletis Pharma Inc., a prominent player in the biotechnology sector, is dedicated to the development and discovery of antiviral drugs aimed at addressing unmet medical needs in antiviral, cancer, and fatty liver disease domains. The company, headquartered in Hangzhou, China, operates on a global scale and is listed on the Hong Kong Stock Exchange.

Financial Snapshot

As of June 5, 2025, Ascletis Pharma Inc. reported a close price of 7.65 HKD. The company’s stock has experienced significant volatility over the past year, with a 52-week high of 9.28 HKD on March 23, 2025, and a 52-week low of 0.76 HKD on August 22, 2024. The market capitalization stands at 6.92 billion HKD. However, the company’s price-to-earnings ratio is currently at -23.83, indicating a challenging financial performance.

Industry Focus

Ascletis Pharma Inc. is focused on the biotechnology industry, specifically targeting the development of antiviral medications. The company’s research and development efforts are directed towards addressing critical health issues, including antiviral infections, cancer, and fatty liver disease. This strategic focus positions Ascletis Pharma as a key player in the healthcare sector, aiming to fill significant gaps in medical treatment options.

Global Operations

With its main base in Hangzhou, China, Ascletis Pharma Inc. extends its operations globally, leveraging international partnerships and collaborations to advance its research and development initiatives. The company’s commitment to innovation and addressing unmet medical needs is reflected in its strategic global presence.

For more information, Ascletis Pharma Inc. can be accessed through its official website at https://www.ascletis.com/ .